Drug Trial Radar · NCT06865651
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
May 22, 2025
Primary completion
Aug 23, 2027
Study completion Sep 28, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to explore the effect and Mechanism of Action (MoA) of remibrutinib (LOU064) vs. placebo on clinical outcomes in participants with Chronic Urticaria (CU), including both Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CINDU).
Conditions
- Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Interventions
RemibrutinibDrug
tablets
PlaceboDrug
tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute change from baseline in the weekly most bothersome symptom Numeric Rating Scale (NRS) score on the Urticaria Symptom Daily Diary (USDD)Time frame: Baseline, Week 6
- Absolute change from baseline in Urticaria Control Test 7 (UCT7) weekly scoresTime frame: Baseline, Week 6
Locations
17 sites in 5 countries. Site status is shown where the registry gives one.
Ziaderm Research LLC
North Miami Beach, Florida · Recruiting
Endeavor Health
Glenview, Illinois · Recruiting
Novartis Investigative Site
Grenoble, France · Recruiting
Novartis Investigative Site
Montpellier, France · Recruiting
Novartis Investigative Site
Paris, France · Recruiting
Novartis Investigative Site
Pierre-Bénite, France · Recruiting
Novartis Investigative Site
Berlin, Germany · Recruiting
Novartis Investigative Site
Mainz, Germany · Withdrawn
Novartis Investigative Site
Tübingen, Germany · Recruiting
Novartis Investigative Site
Dresden, Saxony, Germany · Recruiting
Novartis Investigative Site
Poznan, Poland · Recruiting
Novartis Investigative Site
Rzeszów, Poland · Withdrawn
Novartis Investigative Site
Warsaw, Poland · Withdrawn
Novartis Investigative Site
Alicante, Spain · Recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Barcelona, Catalonia, Spain · Recruiting
Novartis Investigative Site
Pamplona, Navarre, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.